December 19, 2011
Recently, the T1DAL (ITN045AI Rigby) branded study website launched an online patient recruitment tool to enhance the pre-screening process. This pre-screener is a one-page online questionnaire that includes a few health-related questions relevant for participation in this clinical research study. If the patient passes the preliminary questionnaire, he/she can choose to be contacted by a T1DAL study coordinator to discuss study participation and schedule a screening appointment, if necessary.
The brief online questionnaire can be completed in a few minutes and is designed as a tool to facilitate the patient recruitment process for those individuals that learn about the T1DAL study via online methods. The team hopes that this online tool will offer a more direct, systematic and time-saving method for connecting potential participants with T1DAL study site personnel.
See www.t1dal.org/qualification-form
The T1DAL study (Inducing Remission in New-onset Type 1 Diabetes with Alefacept) is a phase II, randomized, placebo-controlled clinical research trial examining the safety and efficacy of alefacept in individuals recently diagnosed with type 1 diabetes mellitus. The study is investigating whether alefacept (Amevive®) will slow or halt the destruction of beta cells in the pancreas that occurs during type 1 diabetes. Eligible patients must be between the ages of 12 to 35 years and diagnosed with type 1 diabetes within 3 months of enrollment in the trial.
More Information